Search

Jun Kuai

from Lexington, MA
Age ~57
Get Report
Also known as:
Jun Zhang, Gun Zhang, Jun Kual, Kuai Jun
Phone and address:
15 Farmcrest Ave, Lexington, MA 02421
(781) 290-7640
Related to:
Nan Zhang, 41
Connected to:
Randy Kual, 60Ashley K Kualii, 40Larry D Kuamoo, 76Angela E Kuan, 78Calvin C Kuan, 56Frank C Kuan, 70Gary M Kuan, 55James Kuan, 40Jen C KuanJenny Kuan, 43

Jun Kuai Phones & Addresses

  • 15 Farmcrest Ave, Lexington, MA 02421 (781) 290-7640
  • Andover, MA
  • Somerville, MA
  • Decatur, GA
  • 117 Harvard St, Cambridge, MA 02139
  • Malden, MA
  • Allston, MA
  • Rockville, MD
  • 15 Farmcrest Ave, Lexington, MA 02421

Emails

j***i@hotmail.com

Resumes

Resumes

Jun Kuai Photo 1

Senior Director, Biochemistry And Biophysics

View page
Location:
15 Farmcrest Ave, Lexington, MA 02421
Industry:
Biotechnology
Work:
Pfizer since Jul 2011
Principal Scientist
Pfizer Jan 2010 - Jul 2011
Principal Scientist
Wyeth Jul 2000 - Jan 2010
Senior Research Scientist II
Education:
Emory University 2000
Doctor of Philosophy (Ph.D.), Biochemistry, Cell and Developmental Biology
Skills:
Drug Discovery
Cell Biology
Immunology
Biochemistry
Assay Development
Target Identification
In Vitro
Cell
Antibodies
Protein Chemistry
Elisa
Pharmacology
Flow Cytometry
Protein Purification
Molecular Biology
Translational Medicine
Purification
Cell Based Assays
Biomarker Discovery
Biopharmaceuticals
Animal Models
Cro
Biomarkers
Monoclonal Antibodies
Glp
Clinical Development
Drug Design
Inflammation
Small Molecules
Protein Engineering
Drug Development
Oncology
Biology
Translational Research
Laboratory
Cell Culture
Lifesciences
Immunoassays
Lead Change
In Vivo
Pharmacokinetics
Validation
High Throughput Screening
Biotechnology
Languages:
English
Mandarin
Jun Kuai Photo 2

Senior Scientist At Pfizer

View page
Position:
Senior Scientist at Pfizer
Location:
Greater Boston Area
Industry:
Pharmaceuticals
Work:
Pfizer
Senior Scientist

Publications

Us Patents

Composition And Method For Modulating An Inflammatory Response

View page
US Patent:
20040038299, Feb 26, 2004
Filed:
Feb 10, 2003
Appl. No.:
10/361270
Inventors:
Jun Kuai - Lexington MA, US
Joseph Wooters - Brighton MA, US
Elliott Nickbarg - Belmont MA, US
Yongchang Qiu - Arlington MA, US
Lih-Ling Lin - Concord MA, US
International Classification:
G01N033/53
C07K014/705
US Classification:
435/007100, 530/350000
Abstract:
The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LTR) modulators, which activate or inhibit LTR signaling. LTR modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LTR complex proteins that act as LTR activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LTR, its ligands, LIGHT and LT12, or its intracellular binding partners, that function to regulate LTR signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LTR signaling is provided.

Methods And Reagents Relating To Inflammation And Apoptosis

View page
US Patent:
20060078944, Apr 13, 2006
Filed:
Aug 1, 2003
Appl. No.:
10/523328
Inventors:
Jun Kuai - Cambridge MA, US
Lih-Ling Lin - Concord MA, US
Joseph Wooters - Brighton MA, US
Elliott Nickbarg - Belmont MA, US
International Classification:
G01N 33/53
C12P 21/02
C12N 9/12
C07K 14/535
C07K 14/715
US Classification:
435007100, 435320100, 435325000, 435069500, 530350000, 530351000, 435194000
Abstract:
The present invention relates to, among other embodiments, protein complexes which include tumor necrosis factor alpha (TNF-α) and/or tumor necrosis factor alpha receptor (TNFR). Preferably, the complexes comprise at least one polypeptide selected from the group consisting of: NF-κB activating kinase (NAK), RasGAP3, TRCP1, and TRCP2. The present invention further provides assays of identifying a compound for modulating the stability and activity of the complex. Also provided are methods of modulating apoptosis and inflammation, as well as treating TNF-α related diseases.

Inflammation Treatment, Detection And Monitoring Via Trem-1

View page
US Patent:
20080247955, Oct 9, 2008
Filed:
Jan 16, 2008
Appl. No.:
12/009166
Inventors:
Jun Kuai - Lexington MA, US
Ken Dower - Medford MA, US
Jeffrey Lawrence Feldman - Arlington MA, US
Debra Denene Pittman - Windham MA, US
David Gunther Winkler - Arlington MA, US
Lih-Ling Lin - Concord MA, US
Scott Alan Jelinsky - Acton MA, US
Cara Williams - Methuen MA, US
International Classification:
A61K 49/00
A61K 31/7088
A61K 39/00
C07K 16/00
A61K 38/02
G01N 33/53
A61K 39/395
C07H 21/02
A61P 37/06
US Classification:
424 92, 514 44, 4241841, 5303881, 4241411, 536 231, 435 72, 435 71, 514 12
Abstract:
The present invention provides methods of treating inflammatory diseases/disorders in a subject by inhibiting/antagonizing TREM-1 expression/activity/signal transduction and/or DAP12/TyroBP expression and/or activity. Methods of detecting the presence of inflammatory disease in a subject by detecting TREM-1 and/or DAP12/TyroBP expression and/or activity in the subject or a sample obtained therefrom, wherein increased expression or activity is indicative of the inflammatory disease are also included. The present invention further provides methods for assessing the efficacy of a TREM-1-modulating agent administered to a patient by detecting levels of secreted phosphoprotein 1 (SPP1) and/or one or more other biomarkers in the patient or in a sample from the patient.

Composition And Method For Modulating An Inflammatory Response

View page
US Patent:
20080248460, Oct 9, 2008
Filed:
Jul 6, 2007
Appl. No.:
11/825385
Inventors:
Jun Kuai - Lexington MA, US
Joseph L. Wooters - Brighton MA, US
Elliott Nickbarg - Belmont MA, US
Yongchang Qiu - Arlington MA, US
Lih-Ling Lin - Concord MA, US
International Classification:
C12Q 1/70
C12Q 1/02
C12Q 1/68
G01N 33/573
US Classification:
435 5, 435 29, 435 6, 435 792
Abstract:
The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LTβR) modulators, which activate or inhibit LTβR signaling. LTβR modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LTβR complex proteins that act as LTβR activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LTβR, its ligands, LIGHT and LTβ1α2, or its intracellular binding partners, that function to regulate LTβR signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LTβR signaling is provided.

Platelet-Derived Growth Factor B Specific Antibodies And Compositions And Uses Thereof

View page
US Patent:
20140134176, May 15, 2014
Filed:
Nov 8, 2013
Appl. No.:
14/075755
Inventors:
- New York NY, US
Gregory CARVEN - Maynard MA, US
Jun KUAI - Lexington MA, US
Lydia MOSYAK - Newton MA, US
Shinji OGAWA - Setagaya, JP
Dirk PONSEL - Germering, DE
Robert RAUCHENBERGER - Farchant, DE
Assignee:
Pfizer Inc. - New York NY
International Classification:
C07K 16/22
US Classification:
4241391, 5303892, 536 2353, 5303879, 4241581, 4352523, 435335, 4353201, 435 696
Abstract:
The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to PDGF-B. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of PDGF-B mediated diseases, disorders or conditions.
Control profile
Jun Kuai from Lexington, MA, age ~57 Get Report